Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2017-03-21

Clinical Trial Update: A Research Study to Evaluate the Effectiveness of Dexmedetomidine in Preventing Delirium After Heart Surgery [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating dexmedetomidine to prevent delirium after heart surgery has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dexmedetomidine (Dexmedetomidine)

Snippet

Sponsor: Hospira, now a wholly owned subsidiary of Pfizer | Conditions: Delirium | Phase 3 | Status: WITHDRAWN